SEC Form 4 · accession 0001562180-16-001573
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Robichaud
Officer — Chief Scientific Officer
Period of report
Feb 8, 2016
Accepted (ET)
Feb 10, 2016 · 3:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $28.63 | Feb 8, 2016 | A | 25,000 | A | — | Feb 8, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The securities awarded on 2/08/2016 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 6,250 shares of common stock shall vest on the one year anniversary of the Vesting Start Date with 18,750 shares vesting in 36 equal monthly installments thereafter.
Remarks
Chief Scientific Officer